NDAOPHTHALMICSOLUTION
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
RYZUMVI (phentolamine mesylate) by Septodont is soft-tissue anesthesia and the associated functional deficits is not fully understood. First approved in 2023.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYZUMVI (phentolamine mesylate) is an ophthalmic solution containing an alpha-adrenergic antagonist approved in September 2023 by the FDA. The drug works by blocking alpha-adrenergic receptors on vascular smooth muscle, producing vasodilatation and increased local blood flow. It is indicated for reversal of soft-tissue anesthesia and associated functional deficits following local anesthetic administration.
Growth13.3 years to LOE
Early-stage product in growth phase with no direct competitors, suggesting opportunity for rapid team expansion and market development roles.
Mechanism of Action
soft-tissue anesthesia and the associated functional deficits is not fully understood. Phentolamine mesylate, the active ingredient in OraVerse, produces an alpha-adrenergic block of relatively short duration resulting in vasodilatation when applied to vascular smooth muscle. In an animal model,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RYZUMVI represents an early-stage specialty pharmaceutical opportunity in a niche ophthalmologic market with zero competition and strong patent protection through 2039. Career growth potential is high during the growth phase, with roles focused on market development, physician engagement, and establishing clinical adoption in eye care settings.
Brand Manager
Worked on RYZUMVI at Septodont? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.